[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"minimally-invasive-surgical-procedures\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:minimally-invasive-surgical-procedures":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,49,88,127,152,177,206,249,282,311,338],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100644469","bone-substitutes-and-nipsa-in-intrabony-periodontal-defects-a-randomized-controlled-trial-100644469",false,"NCT07671963","Bone Substitutes and NIPSA in Intrabony Periodontal Defects: A Randomized Controlled Trial","Regenerative Therapy of Intrabony Periodontal Defects Using Bone Substitutes and a Minimally Invasive Nonincised Papilla Surgical Approach - A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of Stage III periodontitis\n* At least one intrabony periodontal defect with probing depth \\> 5 mm following completion of non-surgical periodontal therapy\n* Full-mouth plaque score (FMPS) \\\u003C 20%\n* Full-mouth bleeding score (FMBS) \\\u003C 20%\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Systemic medical contraindications to periodontal surgery\n* History of head and neck radiotherapy\n* Poor oral hygiene or lack of motivation\u002Fcompliance\n* Uncontrolled diabetes mellitus\n* Pregnancy or lactation\n* Treatment with antiresorptive medications or other drugs affecting bone remodeling\n* Heavy smoking (\\>20 cigarettes\u002Fday)",true,"ALL","18 Years","80 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","This multicenter randomized controlled clinical trial aims to compare the clinical, radiographic, microbiological and molecular outcomes of two collagenated xenogeneic bone substitutes (GTO® and GenOs®) used in combination with the Non-Incised Papilla Surgical Approach (NIPSA) for the treatment of intrabony periodontal defects. The study will evaluate whether differences exist between the two biomaterials with respect to clinical attachment gain, defect resolution, wound healing and biological markers of regeneration.",[28,29,30],"Periodontitis (Stage 3)","Minimally Invasive Surgical Procedures","Bone Substitutes",[32,33,34,35],"periodontitis","regenerative treatment","NIPSA","bone substitutes","RECRUITING","2026-06-22",{"date":39,"type":40},"2026-06-26","ACTUAL",{"date":42,"type":22},"2026-07-01",{"date":44,"type":22},"2027-03-01",{"name":46,"class":47},"University of Belgrade","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":71,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100644230","phase-4-cyclobenzaprine-for-postoperative-pain-in-minimally-invasive-hysterectomy-100644230","NCT07664956","Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy","Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age \\>18yo\n* Female\n* English speaking\n* Undergoing (robotic assisted or classic) total laparoscopic hysterectomy ± unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy\n* If other procedures such as lysis of adhesions, excision of endometriosis, or ureterolysis are indicated based on intraoperative evaluation, those patients may still be included\n* Surgery took place at ChristianaCare Hospitals\n* No allergies or contraindications to standard of care post operative pain medications (acetaminophen, NSAIDs, narcotics) or cyclobenzaprine\n\nExclusion Criteria:\n\n* Age \\\u003C18yo\n* Male\n* Pregnant, breastfeeding\n* Non-English speaking\n* Primary procedures other than laparoscopic hysterectomy\n* Laparoscopic myomectomy\n* Laparoscopic resection of endometriosis\n* Laparoscopic unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy ± unilateral or bilateral cystectomy without hysterectomy\n* Hysteroscopic procedures\n* Bartholin gland marsupialization\n* Operations that are scheduled as or converted to the open approach\n* Procedures with planned or unplanned bladder or bowel surgery\n* Allergies or contraindications to standard post operative pain control medications (acetaminophen, NSAIDs, narcotics), such as kidney or liver damage\u002Ffailure, bariatric surgery, history of gastric ulcer, etc.\n* Chronic pain issues, whether self-diagnosed or by a physician, currently undergoing management\n* Currently undergoing medication assisted treatment for opioid use disorder\n* Currently using opioids consistently\n* Allergies or contraindications to cyclobenzaprine:\n* Absolute: use of MAO inhibitors within 14 days, recent heart attack, congestive heart failure, heart block or other conduction abnormalities, cardiac arrhythmias, hyperthyroidism, history of serotonin syndrome\n* Allergies or contraindications to inactive ingredients in Flexeril, such as lactose\n* Patient's receiving gabapentin at baseline or postoperatively, due to potential sedating effects, or other sedating drugs such as scheduled benzodiazepines and barbiturates","FEMALE",{"count":58,"type":22},36,[60],"PHASE4","Typical postoperative pain control after minimally invasive hysterectomy includes ibuprofen, acetaminophen, and a short course of narcotics. The purpose of this study is to see if adding cyclobenzaprine to this regime improves pain control and lessens narcotic use.",[29,63,64,65,66,67,68,69,70],"Abnormal Uterine Bleeding, Unspecified","Adenomyosis of Uterus","Fibroid Uterus","Chronic Pelvic Pain","Endometriosis","Menorrhagia","Endometritis","Adnexal Diseases",[72,73,74,75,76,77],"cyclobenzaprine","flexeril","hysterectomy","minimally invasive hysterectomy","pain control","multimodal pain control","NOT_YET_RECRUITING","2026-06-18",{"date":81,"type":40},"2026-06-24",{"date":42,"type":22},{"date":84,"type":22},"2026-12-01",{"name":86,"class":47},"Christiana Care Health Services",1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":126},"100172884","product-surveillance-registry-100172884","NCT01524276","Product Surveillance Registry","Medtronic Product Surveillance Registry","PSR","Inclusion Criteria:\n\n* Patient or legally authorized representative provides written authorization and\u002For consent per institution and geographical requirements\n* Patient has or is intended to receive or be treated with an eligible Medtronic product\n* Patient within enrollment window relative to therapy initiation or meets criteria for retrospective enrollment\n\nExclusion Criteria:\n\n* Patient who is, or will be, inaccessible for follow-up\n* Patient with exclusion criteria required by local law\n* Patient is currently enrolled in or plans to enroll in any concurrent drug and\u002For device study that may confound results",{"count":97,"type":22},100000,"OBSERVATIONAL","The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.",[101,102,103,104,105,106,107,108,109,29,110,111,112,113,114,115],"Cardiac Rhythm Disorders","Urological Disorders","Neurological Disorders","Cardiovascular Disorders","Digestive Disorders","Intracranial Aneurysm","Mechanical Circulatory Support","Respiratory Therapy","Aortic, Peripheral Vascular and Venous Disorders","Diagnostic Techniques and Procedures","Surgical Procedures, Operative","Renal Insufficiency","Neurovascular","Coronary Artery Disease","Ear, Nose and Throat Disorder","2026-06-15",{"date":118,"type":40},"2026-06-17",{"date":120,"type":4},"2012-01",{"date":122,"type":22},"2040-01",{"name":124,"class":125},"Medtronic","INDUSTRY",395,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":135,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":87},"100643494","assessment-of-renal-perfusion-using-ultrasound-and-near-infrared-spectroscopy-in-patients-undergoing-minimally-invasive-abdominal-surgery-100643494","NCT07635160","Assessment of Renal Perfusion Using Ultrasound and Near-Infrared Spectroscopy in Patients Undergoing Minimally Invasive Abdominal Surgery","Prospective Observational Evaluation of Renal Perfusion Using Doppler Ultrasonography and Near-Infrared Spectroscopy in Patients Undergoing Elective Minimally Invasive Abdominal Surgery","RRI-NIRS","Inclusion Criteria:\n\n* Patients aged 18 to 80 years\n* Patients with ASA physical status I, II, or III\n* Patients undergoing elective minimally invasive abdominal surgery for any reason\n* Patients whose expected surgical duration is longer than 1 hour\n\nExclusion Criteria:\n\n* Body mass index greater than 35 kg\u002Fm²\n* Severe respiratory system disease\n* Severe heart failure, NYHA class III-IV\n* Presence of a cardiac pacemaker or cardiac defibrillator implant\n* Progressive neuromuscular disease\n* High intra-abdominal pressure\n* Sudden deterioration of general condition\n* Incomplete clinical or laboratory data\n* Refusal to participate in the study\n* Conversion to open surgery",{"count":136,"type":22},51,"This prospective observational study aims to evaluate renal perfusion in adult patients undergoing elective minimally invasive abdominal surgery. Renal perfusion will be assessed using two non-invasive monitoring techniques: Doppler ultrasonography-derived Renal Resistive Index (RRI) and Near-Infrared Spectroscopy (NIRS)-derived renal regional oxygen saturation (rSO₂).\n\nMeasurements will be obtained at predefined perioperative time points, including after induction of anesthesia, during pneumoperitoneum, before extubation, and during the early postoperative period. Perioperative changes in renal perfusion parameters will be analyzed and correlated with clinical variables such as intra-abdominal pressure, pneumoperitoneum duration, hemodynamic parameters, fluid administration, urine output, and postoperative renal function.\n\nThe study also aims to investigate the relationship between intraoperative renal perfusion changes and the development of postoperative acute kidney injury. The findings may contribute to improved perioperative monitoring and optimization of renal perfusion during minimally invasive abdominal surgery.",[139,29,140],"Renal Perfusion","Acute Kidney Injury",[142],"Kidney Perfusion,Renal Resistive Index,Near-Infrared Spectroscopy,Acute Kidney Injury,Laparoscopic Surgery","2026-06-03",{"date":145,"type":40},"2026-06-09",{"date":147,"type":40},"2026-01-07",{"date":149,"type":22},"2027-01-07",{"name":151,"class":47},"Istanbul University - Cerrahpasa",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":87},"100621399","phase-2-omitting-nasogastric-tube-decompression-in-minimally-invasive-pancreaticoduodenectomy-100621399","NCT07370116","Omitting Nasogastric Tube Decompression in Minimally Invasive Pancreaticoduodenectomy","Safety and Feasibility of Omitting Nasogastric Decompression in Minimally Invasive Pancreaticoduodenectomy: a Multicenter Non-inferiority Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age between 18 years and 75 years.\n2. Indication for MIPD confirmed by MDT evaluation.\n3. Ability to understand trial requirements and willingness to adhere to study protocols.\n4. Written informed consent obtained before registration.\n5. Curative-intent treatment consistent with international clinical guidelines.\n\nExclusion Criteria:\n\n1. Requirement of partial or total pancreatectomy or other palliative procedures, or presence of distant metastases (peritoneal, hepatic, distant nodal, or other organ involvement); therefore, these patients are not candidates for MIPD.\n2. American Society of Anaesthesiologists (ASA) Physical Status ≥ IV.\n3. Pregnant or breastfeeding women.\n4. Severe psychiatric disorders.\n5. History of other malignancy.\n6. Neoadjuvant chemoradiotherapy prior to surgery.\n7. Body mass index \\>35 kg\u002Fm2.\n8. History of nasopharyngeal, gastric or oesophageal surgery.\n9. Preoperative gastrointestinal obstruction.\n10. Contraindications to nasogastric intubation, including recent caustic ingestion, oesophageal stricture\u002Fdiverticulum, or maxillofacial trauma.\n11. Participation in any other clinical trials within 3 months.","75 Years",{"count":161,"type":22},200,[163],"PHASE2","This study will evaluate two perioperative nasogastric tube strategies in patients undergoing laparoscopic pancreatoduodenectomy. The goal is to determine whether routine omission of a nasogastric tube is not worse than routine nasogastric tube placement in terms of overall complications and postoperative recovery.\n\nParticipants will be randomly assigned to one of two groups. Each group will receive the assigned nasogastric tube strategy during and after surgery, and will be followed during the hospital stay and after discharge for up to postoperative 90 days. Information will be collected from routine clinical care, including discomfort score, symptoms, imaging or laboratory tests when clinically indicated, and postoperative outcomes.\n\nThe main outcome of this study is the overall burden of postoperative complications within 30 days after surgery, measured using the Comprehensive Complication Index, which summarizes all complications into a single score. Secondary outcomes include rates of pancreas surgery-specific complications (such as delayed gastric emptying, pancreatic fistula, bile leak, bleeding, and chyle leak), other abdominal and pulmonary complications, and organ dysfunction (including kidney injury, sepsis, and new cardiac dysfunction). The study will also evaluate patient discomfort related to the nasogastric tube (pain\u002Fdiscomfort scores), the need for nasogastric tube reinsertion, postoperative recovery milestones (ability to resume oral intake and length of hospital stay), healthcare costs, and all-cause mortality at 30 and 90 days after surgery.",[166,167,29],"Pancreaticoduodenectomy","Nasogastric Tube Decompression","2026-03-11",{"date":170,"type":40},"2026-03-12",{"date":172,"type":22},"2026-04-01",{"date":174,"type":22},"2026-09",{"name":176,"class":47},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":184,"targetDuration":186,"studyType":98,"phases":4,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":87},"100626150","pain-evaluation-across-robotic-and-laparoscopic-surgery-for-colorectal-procedures-100626150","NCT07431892","Pain Evaluation Across Robotic and Laparoscopic Surgery for Colorectal Procedures","PEARL","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Signed informed consent\n* Meeting inclusion requirements of the hospital's Enhanced Recovery Protocol (RICA program), including:\n* Adequate cognitive status\n* ASA (American Society of Anesthesiologists) classification I, II, or III\n* Elective colon surgery (right or left hemicolectomy) for malignant disease\n* Planned laparoscopic or robotic surgical approach\n* Preoperative evaluation completed as per RICA protocol (nutritional, nursing, anesthetic, and pharmacy assessments)\n\nExclusion Criteria:\n\n* Patients with a preoperative decision for open surgery\n* Patients undergoing rectal surgery (partial or total mesorectal excision without protective stoma)\n* Patients with inflammatory bowel disease requiring colorectal resection\n* Patients requiring multivisceral resection due to oncologic indications identified intraoperatively\n* Extraction incision different from Pfannenstiel approach\n* Current or past history of chronic opioid use or opioid abuse\n* Current or past history of benzodiazepine use or abuse\n* Chronic use of analgesics for other comorbid medical conditions\n* Current or past history of recreational drug use or abuse\n* Non-compliance with the RICA protocol, including:\n* Lack of preoperative nutritional, nursing, anesthetic, or pharmacy evaluation\n* Non-adherence to preoperative care protocols (e.g., premedication, fasting, carbohydrate loading, thromboembolism prophylaxis, antibiotic prophylaxis, anesthetic care guidelines)",{"count":185,"type":22},80,"30 Days","Minimally invasive surgery for colorectal conditions, such as laparoscopic or robotic surgery, has been shown to offer benefits over traditional open surgery. These benefits include less pain after surgery, shorter hospital stays, and fewer complications.\n\nThis study aims to compare two types of minimally invasive surgery-laparoscopic and robotic surgery-to determine which approach results in less postoperative pain for patients undergoing colon or rectal surgery. The central hypothesis is that robotic surgery, due to its higher precision and reduced tissue trauma, will lead to lower pain levels after surgery.\n\nThe study will enroll adult patients scheduled for elective colorectal surgery at the Hospital General Universitario Gregorio Marañón in Madrid. Participants will undergo either laparoscopic or robotic surgery based on clinical availability and surgical planning, as long as they meet all inclusion criteria under the hospital's enhanced recovery protocol (RICA program).\n\nResearchers will assess patients' pain levels at different time points after surgery (immediately after recovery, at 24, 48, and 72 hours, and at discharge) using validated pain scales. The use of pain medications, hospital stay duration, complication rates, and quality of life up to 12 months after surgery will also be measured.\n\nAll patient data will be collected anonymously using a secure electronic system (REDCap). The study will last approximately 2 years and include about 80 patients (40 in each group).\n\nThe results could help surgeons and hospitals choose the most effective surgical approach to reduce postoperative pain and improve patient recovery in colorectal surgery.",[29,189],"Colon Cancer Patients",[191,192,193,194,195,196],"colorectal surgery","minimally invasive surgery","robotic surgery","laparoscopic surgery","postoperative pain","Nociception Level Index (NOL)","2026-02-18",{"date":199,"type":40},"2026-02-25",{"date":201,"type":40},"2025-09-01",{"date":203,"type":22},"2028-09-01",{"name":205,"class":47},"Hospital Central de la Defensa Gómez Ulla",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":23,"phases":217,"briefSummary":218,"conditions":219,"keywords":230,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":87},"100572340","optimal-perioperative-pain-control-in-minimally-invasive-abdominal-cancer-surgery-100572340","NCT06731998","Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery","Evaluating Optimal Perioperative Pain Management: A Prospective Randomized Control Trial of Laparoscopic Transversus Abdominis Plane Block With Local Anesthetic, Laparoscopic Transversus Abdominis Plane Block Alone, and Local Anesthetic Alone in Minimally Invasive Oncologic Surgery","LapTAP","Inclusion Criteria:\n\n1. Male and female patients age ≥ 18 - 89\n2. Patients scheduled for elective (clinically indicated) hepatic, gastric, biliary, pancreatic, gynecologic, colorectal, other GI Minimally invasive oncologic surgery.\n3. Patients who have provided informed consent to participate in the study.\n4. Patients with an American Society of Anesthesiologists (ASA) physical status classification of I, II, or III.\n5. Patients undergoing procedures anticipated to last more than 1 hour but less than 8 hours.\n6. Patients able to understand and self-report pain using the designated pain Visual Analog Scale\n\nExclusion Criteria:\n\n1. Patients age less than 18 or ≥ 90\n2. Pre-existing hepatic dysfunction, cirrhosis\n3. Patients with an ASA classification of IV or higher.\n4. Patients with chronic pain disorders or on long-term opioid or analgesic therapy.\n5. Patients with known contraindications to the study drugs or procedures (e.g., allergy to LA or contraindications to LapTAP).\n6. Patients with cognitive impairments or psychiatric conditions that could interfere with pain assessment or understanding of informed consent.\n7. Patients unable to understand the language in which consent and study-related information are provided (The study and the study-related information will be in the English Language)..\n8. Patients who have undergone major surgery within the last 6 months.\n9. Female patients who are pregnant.\n10. Patients currently enrolled in another clinical trial that might interfere with the outcome measures of this study.","89 Years",{"count":216,"type":22},48,[25],"This is a research study to evaluate the effectiveness of 3 different types of routine pain management regimens used during clinically indicated, minimally invasive oncologic (cancer) surgery. This project is considered \"Research\" and participation is voluntary. Upon enrollment in this study, the research team will collect data from the patient's medical records. The patient will undergo all of the normal testing and procedures required pre-operatively (standard of care). The study team will then randomly assign the patient (like a flip of a coin) to one of three different study arms for pain management during surgery:\n\n1. Laparoscopic Transversus Abdominis Plane Block (LapTAP) with Local Anesthetic (LA)\n2. Laparoscopic Transversus Abdominis Plane Block (LapTAP) only\n3. Local Anesthetic (LA) only The patient will receive standard pre- and post-operative care according to clinical guidelines (routine care). The study team will collect information from the patient's medical record for the first 24 hours after their surgery and upon discharge. This information will include pain scores, amount of medication required, any side effects the patient may have experienced, and satisfaction with pain control. Participation in the study will end upon discharge from the hospital.",[220,221,222,223,224,225,226,227,228,229,29],"Oncologic Surgery","Cancer","Cancer Surgery","Hepatic Cancer","Gastric (Cardia, Body) Cancer","Biliary Tract Cancer","Pancreatic Cancer Resectable","Gynecologic Cancers","Gastrointestinal Cancers","Colorectal Cancer",[231,232,233,234,235,236,237,238,239],"Laparoscopic Transversus Abdominis Plane Block","Local Anesthetic","Laparoscopic Surgical Procedure","pain management","cancer","cancer surgery","oncologic surgery","perioperative pain management","minimally invasive surgical procedures","2025-09-15",{"date":242,"type":40},"2025-09-18",{"date":244,"type":40},"2025-02-05",{"date":246,"type":22},"2026-12",{"name":248,"class":47},"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":56,"minAge":18,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":260,"conditions":261,"keywords":266,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":87},"100583021","comparison-of-transvaginal-paracervical-and-transperitoneal-approaches-in-lymphadenectomy-during-v-notes-surgery-for-patients-diagnosed-with-endometrial-cancer-100583021","NCT06870903","Comparison of Transvaginal Paracervical and Transperitoneal Approaches in Lymphadenectomy During v-NOTES Surgery for Patients Diagnosed With Endometrial Cancer","ENDONOTE","Patient Selection and Data Collection This study will be implemented in a single institution, Diyarbakır Gazi Yaşargil Training and Research Hospital, which functions as a tertiary cancer treatment facility.\n\nBetween March 2025 and December 2025, patients with newly diagnosed clinical early stage (FIGO 2023 stages 1 and 2) endometrial cancer who will be treated with laparoscopic surgical staging with SLN mapping at our institution will be randomized into groups. The research procedure has been approved by the ethics committee\u002Finstitutional review board of Diyarbakır Gazi Yaşargil Training and Research Hospital and informed consent signed by the patient will be included in each table reviewed.\n\nEligible participants will be required to give informed consent to participate in the study.\n\nInclusion criteria will include\n\n* Participants whose endometrial biopsy resulted in endometrial cancer and whose disease will be detected limited to the uterus using imaging modalities (computed tomography \\[CT\\], magnetic resonance imaging or Fluorine-18 fluorodeoxyglucose positron emission tomography\u002FCT)\n* Absence of synchronous malignancies.\n* No neoadjuvant treatment before surgical intervention.\n\nExclusion criteria will include:\n\n* Contraindications to using methylene blue dye or contraindications to the vNOTES procedure.\n* Patients who have had previous malignancy surgery.\n* Severe, deeply penetrating endometriosis or enlarged uterus that may require forced vaginal extraction\n* Receiving neodajuvant therapy","85 Years",{"count":258,"type":22},52,[25],"The aim of this study is to compare two types of lymphadenectomy (transperitoneal vs. paracervical) during the lymphadenectomy phase of endometrial cancer staging surgery performed using V-NOTES, a new and advanced technique. This study seeks to optimize the V-NOTES technique for endometrial cancer staging. This randomized, prospective, controlled study will include patients diagnosed with endometrial cancer via histology, following physical examination and imaging, and who are electively scheduled for the V-NOTES endometrial cancer staging procedure. Patients will be randomized into two groups: the transvaginal paracervical lymphadenectomy group and the transperitoneal lymphadenectomy group. The parameters related with surgical and functional outcomes will be compared in both groups.",[262,263,264,29,265],"Endometrial Cancer","Lymphadenectomy","Sentinel Lymph Node Biopsy","Natural Orifice Transluminal Endoscopic Surgery",[267,268,269,270,271,272],"endometrial cancer","V-NOTES","lymphadenectomy","sentinel lymph node","transperitoneal","extraperitoneal","2025-03-17",{"date":275,"type":40},"2025-03-20",{"date":277,"type":40},"2025-03-15",{"date":279,"type":22},"2026-03-01",{"name":281,"class":47},"Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":290,"targetDuration":292,"studyType":98,"phases":4,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":48},"100565166","prolonged-hospital-stay-after-thoracoscopic-anatomical-lung-resections-100565166","NCT06638645","Prolonged Hospital Stay After Thoracoscopic Anatomical Lung Resections","Reasons for Prolonged Hospital Stay After Thoracoscopic Anatomical Lung Resections","PROTRACT","Inclusion Criteria:\n\n* Patients referred for elective minimally invasive (uniportal or multiportal video- or robot-assisted) anatomical lung resection (lobectomy or segmentectomy)\n* Informed consent obtained pre-operatively\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Patients younger than 18 years old\n* Traumatic event as indication for lung resection\n* Non-anatomical lung resections\n* Thoracotomy\n* Patients already hospitalized for other pathologies, pre-existent and not related to the lung surgery\n* Urgent\u002Femergency procedures",{"count":291,"type":22},140,"2 Months","In this study, the reasons for prolonged hospital stay after thoracoscopic (video- or robot-assisted) anatomical lung resections are investigated. Currently, whenever possible, these anatomical lung resections are performed thoracoscopically, as they offer significant improvements in terms of postoperative pain, number of postoperative complications, rehabilitation, tolerance for adjuvant chemotherapy, and length of hospital stay. The development of an 'Enhanced Recovery After Surgery' (ERAS) protocol for lung surgery has further reduced hospital stay and the need for opioids for analgesia. Despite the optimal implementation of the ERAS protocol, there are still patients who need to stay in the hospital longer than the median. The aim of this research is to investigate the reasons for this.",[29,295,296,297,298,299,300,301],"VATS","RATS Surgery","Pulmonary Lobectomy","Pulmonary Segmentectomy","Air Leakage","Postoperative Complication","Pain Postoperative","2025-01-13",{"date":304,"type":40},"2025-01-15",{"date":306,"type":40},"2024-11-12",{"date":308,"type":22},"2025-12-31",{"name":310,"class":47},"University Hospital, Ghent",{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":23,"phases":321,"briefSummary":322,"conditions":323,"keywords":326,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":5},"100474660","dutch-intracerebral-hemorrhage-surgery-trial-100474660","NCT05460793","Dutch Intracerebral Hemorrhage Surgery Trial","Dutch ICH Surgery Trial; Minimally Invasive Endoscopy-guided Surgery for Spontaneous Supratentorial Intracerebral Hemorrhage","DIST","Inclusion Criteria:\n\n1. Age 18 years or older;\n2. NIHSS ≥ 2;\n3. Supratentorial non-traumatic ICH confirmed by non-contrast CT, without a CT-angiography confirmed causative vascular lesion (e.g. aneurysm, arteriovenous malformation \\[AVM\\], dural arteriovenous fistula \\[DAVF\\], cerebral venous sinus thrombosis \\[CVST\\]), or other known underlying lesion (e.g. tumor, cavernoma);\n4. Minimal hematoma volume of 10 mL;\n5. Intervention can be started within 8 hours of symptom onset;\n6. Written informed consent (deferred).\n\nExclusion Criteria:\n\n1. Considerable pre-stroke dependency in activities of daily living, defined as a pre-stroke mRS ≥3;\n2. ICH-GS score ≥11;\n3. Hemorrhage due to hemorrhagic transformation of an infarct;\n4. Untreated coagulation abnormalities, including INR \\>1.3 (point of care measurement allowed), treatment with heparin and treatment with factor Xa inhibitors. Patients on vitamin K antagonist can be included after correction of the INR, and patients on dabigatran (direct thrombin inhibitor) can be included after reversal of dabigatran with idarucizumab;\n5. Moribund (e.g. coning, bilateral dilated unresponsive pupils), or progressively deteriorating clinical course with imminent death;\n6. Pregnancy (note: most patients will be beyond childbearing age);\n7. DIST-INFLAME sub-study: patients that use immunosuppressive or immune-modulating medication.",{"count":320,"type":22},600,[25],"Background: Intracerebral hemorrhage (ICH) accounts for 16-19% of all strokes in Western Europe and contributes profoundly to mortality and disability. Thirty-day case fatality is 40% and of those surviving, only few gain independence. Except for stroke unit care and possibly early blood pressure lowering, there is currently no treatment of proven benefit. Surgical treatment has so far not been proven effective. In the largest trials STICH I and II, and MISTIE III, the median time to treatment was more than 24 hours, which may be an important explanation for the lack of a treatment effect. A recent meta-analysis of randomized controlled trials showed that surgical treatment may be beneficial, in particular with minimally invasive procedures and when performed early. In the Dutch ICH Surgery pilot study, we showed that early minimally invasive endoscopy-guided surgical treatment performed within 8 hours of symptom onset in patients with supratentorial ICH is safe and technically effective. We hypothesize that early minimally invasive endoscopy-guided surgery improves the outcome in patients with supratentorial spontaneous ICH.\n\nObjectives:\n\n1. To study whether minimally invasive endoscopy-guided surgery, in addition to standard medical management, for the treatment of spontaneous supratentorial ICH performed within 8 hours of symptom onset, improves functional outcome in comparison with standard medical management alone;\n2. Determine whether patients treated with minimally invasive surgery develop less perihematomal edema on non-contrast CT at day 6 (±1 day) than controls, and whether the CT perfusion permeability surface-area product around the ICH at baseline modifies this effect (DIST-INFLAME);\n3. Compare immune profiles over time in peripheral venous blood between surgically treated patients and controls (DIST-INFLAME);\n4. To assess the cost-effectiveness and budget-impact of minimally invasive endoscopy-guided surgery for the treatment of spontaneous supratentorial ICH performed within 8 hours of symptom onset.\n\nStudy design: A multicenter, prospective, randomized, open, blinded endpoint clinical trial.\n\nStudy population: We aim to include 600 patients of ≥ 18 years with a spontaneous supratentorial ICH with a hematoma volume of ≥ 10 mL and a NIHSS of ≥ 2. Patients with an aneurysm, arteriovenous malformation (AVM), dural arteriovenous fistula (DAVF), or cerebral venous sinus thrombosis (CVST) as cause of their ICH will be excluded based on the admission CT-angiography. Patients with a known tumor or cavernoma will also be excluded. For DIST-INFLAME (the second and third objective), we will include 200 patients; 100 randomized to intervention and 100 randomized to standard medical management.\n\nIntervention: Patients will be randomized (1:1) to minimally invasive endoscopy-guided surgery performed within 8 hours of symptom onset in addition to standard medical management or to standard medical management alone.\n\nPrimary study outcome: the modified Rankin scale (mRS) score at 180 days. The treatment effect will be estimated with ordinal logistic regression analysis as common odds ratio, adjusted for prespecified prognostic factors.\n\nSecondary outcomes: mRS score at 90 and 365 days; favorable outcome (defined as a mRS 0-2 and 0-3) and all other possible dichotomizations of the mRS at 90, 180 and 365 days; NIHSS at day 6 (±1 day); death, Barthel Index, EuroQol-5D-5L, SS-QOL, iMCQ, iPCQ and iVICQ at 90, 180 and 365 days. Safety outcomes will be death within 24 hours, at 7 and at 30 days and procedure-related complications within 7 days. Technical effectiveness outcomes will be percentage volume reduction based on the baseline CT and CT at 24 hours (± 6 hours), percentage of participants with clot volume reduction ≥70%, and ≥80%, and with remaining clot volume ≤10mL, and ≤15mL, and conversion to craniotomy. In DIST-INFLAME, outcomes will include perihematomal edema at 6 days (±1 day), functional outcome at 180 days and immune and metabolomic profiles at 3 (± 12 hours) and 6 days (±1 day).",[324,29,325],"Intracerebral Hemorrhage","Endoscopic Surgical Procedures",[324,327,328],"Surgical Procedures, Minimally Invasive","Surgical Procedures, Endoscopic","2024-11-18",{"date":331,"type":40},"2024-11-21",{"date":333,"type":40},"2022-11-03",{"date":335,"type":22},"2028-07",{"name":337,"class":47},"Radboud University Medical Center",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":346,"targetDuration":4,"studyType":23,"phases":348,"briefSummary":349,"conditions":350,"keywords":354,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":367},"100538765","phase-2-the-efficacy-of-pipac-and-minimally-invasive-radical-resection-in-high-risk-gastric-cancer-patients-100538765","NCT06295094","The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.","The Efficacy of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC) Combined With CURativE Intent Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. A Multicentre, Randomised, Open-label Phase-II Study","EPICURE","Inclusion criteria\n\n* Gastric or Gastroesophageal junction Siewert type III adenocarcinomas\n* Clinical T3-4a-stages\n\n  1. Any differentiation grade\n  2. Any histological subtype\n* Clinical T2-stage\n\n  a. If poorly differentiated or of the poorly cohesive histological subtype, with or without the presence of signet-ring cells\n* Any clinical T-stage with positivity for malignant cells on abdominal lavage cytology, which is converted to cytology negative in response to neoadjuvant chemotherapy.\n* Any clinical nodal-stage\n* clinical M0-stage (positive abdominal wash cytology, which is converted to cytology negative in response to neoadjuvant therapy, is permitted)\n* Performance status Eastern Cooperative Oncology Group (ECOG) 0-1\n* Age 18 - 80 years\n* Undergoing robotic or laparoscopic D2 gastrectomy\n* Able and willing to provide written informed consent and to comply with the clinical study protocol\n* Fertile women must have a negative pregnancy test at the time of inclusion and must use adequate contraception.\n\nExclusion criteria\n\n* Previous allergic reaction to cisplatin, doxorubicin or other platinum-containing compounds.\n* Renal impairment, defined as glomerular filtration rate (GFR) \\\u003C 40 ml\u002Fmin (Cockcroft-Gault Equation).\n* Myocardial insufficiency, defined as New York Heart Association (NYHA) class 3-4.\n* An impaired liver function, defined as bilirubin ≥ 1.5 x upper normal limit (UNL).\n* An inadequate haematological function, defined as absolute neutrophil count (ANC) \\\u003C1.5 x 109\u002Fl and platelets \\\u003C100 x 109\u002Fl.\n* Any other condition or therapy which, in the investigator's opinion, may pose a risk to the patient or interfere with the study objectives.",{"count":347,"type":22},264,[163],"The goal of this randomized clinical trial is to investigate whether pressurized intraperitoneal chemotherapy (PIPAC), delivered immediately after minimally invasive D2 gastrectomy and repeated 6-8 weeks later, improves 12-month peritoneal disease-free survival in patients with high-risk gastric adenocarcinoma when compared to standard treatment.",[351,352,353,29],"Gastric Cancer","Chemotherapy, Adjuvant","Peritoneal Metastases",[355,356,357],"PIPAC","Gastric cancer","Minimally invasive gastrectomy","2024-03-05",{"date":360,"type":40},"2024-03-06",{"date":362,"type":22},"2024-09",{"date":364,"type":22},"2028-01",{"name":366,"class":47},"Odense University Hospital",5]